A Phase II Trial of CVAD for Treatment of Non-Hodgkin's Lymphoma

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

H Gustafson (Tardif);S Yao;B Goldman;K Lee;C Spier;M LeBlanc;L Rimsza;JR Cernan;TM Habermann;BK Link;MJ Mauer;SL Slager;D Persky;T Miller;RI Fisher;C Ambrosone;M Briehl American Journal of Hematology 89(6):639-645;

PMid: PMID24633940 | PMC number: PMC4137041

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma. a Southwest Oncology Group study

ER Gaynor;JM Unger;TP Miller;TM Grogan;LA White Jr;GM Mills;SP Balcerzak;M Varterasian;M LeBlanc;RI Fisher Journal of Clinical Oncology 19(3):750-755

Infusional therapy with first generation chemosensitizers (CS) results in increased toxicity without improved benefit in untreated lymphoma.

ER Gaynor;TP Miller;S Dahlberg;M LeBlanc;RI Fisher American Society of Clinical Oncology 15:413(#1265)